Quince Therapeutics Inc
Research Quince Therapeutics Inc (QNCX) on Bullrun: market cap USD 31.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQNCX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 31.46M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 33.04M
- Free cash flow-USD 39.66M
Valuation Snapshot
latest market cap is USD 31.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 83.98M | -USD 41.78M | n/a | -1.68 | USD 5.81M | USD 18.03M | -USD 35.71M |
| FY2024 | USD 0 | -USD 56.83M | -USD 32.16M | n/a | -1.31 | USD 6.21M | USD 14.32M | USD 30.15M |
| FY2023 | n/a | -USD 31.39M | -USD 18.45M | n/a | -0.84 | USD 20.75M | USD 13.43M | USD 85.08M |
| FY2022 | n/a | -USD 51.66M | -USD 44.17M | n/a | -1.54 | USD 40.59M | USD 0 | USD 100.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 31.46M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 186.68M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 82.28M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 45.01M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 23.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 379.53M | n/a | n/a | n/a |
About Quince Therapeutics Inc
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Quince Therapeutics Inc's market cap?
Quince Therapeutics Inc's market capitalization is USD 31.46M.
What does Quince Therapeutics Inc do?
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.